article in the australian, page-8

Yes, there is nothing we can do but wait. The independent expert's report is a joke. I can't believe people got paid for that drivel.

What the report really fails to identify clearly is that the value of BOS is in the intellectual property being sold to CBTE. The value of that IP is tied up in the share price of CBTE.

CBTE, in turn, is involved in a reverse takeover by GL Biochem, which may or may not eventuate. CBTE shares are presently trading at about 24 cents. Be sure, if their merger goes ahead, CBTE shares will be above one dollar. Even Tim Boyd valued the deal as worth $5 million to BOS which would require CBTE reaching $2.00 a share.

The way this whole arrangement has been orchestrated I would almost guarantee that there will be no news about CBTE's merger before the BOS meeting on March 19. I wouldn't be surprised if CBTE's meeting occured on or near the same day.

The so-called expert's report gives a 30% discount on trying to sell 1.6 million CBTE shares. Only recently, over two million CBTE shares traded on market. If the GL Biochem merger goes ahead, BOS will have no trouble disposing of the CBTE shares if they so desire.

At this stage, the merger with RGM is irrelevant because the only way to value BOS at this point in time is through the proposed holding of CBTE shares.

Anyway, I'm not complaining. If all these deals come together, recent BOS shareholders should still do alright.
All we can do is wait.